Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder
Information source: Cedars-Sinai Medical Center
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Anxiety Disorders
Intervention: PD 0332334 (Drug); Paroxetine (Drug); Placebo (Other)
Phase: Phase 3
Sponsored by: Cedars-Sinai Medical Center
Lisa H Glassman, B.A., Phone: 310-423-0735, Email: firstname.lastname@example.org
This study is a randomized, double-blind, parallel-group, multi-site, Phase 3, placebo
controlled fixed-dose study of PD 0332334 and paroxetine in 528 outpatients with generalized
anxiety disorder. Subjects will be randomized to the following treatments (132 subjects per
PD 0332334 225 mg BID (450 mg/day), PD 0332334 300 mg BID (600 mg/day), placebo or paroxetine
20 mg QD (20 mg/day).
[QD: once daily, qAM: each morning, BID: twice daily].
The study will consist of 3 phases: an initial screening phase which must be completed 7 to
14 days prior to randomization; an 8-week double-blind treatment phase; and a 2-week
double-blind dose-tapering follow-up phase. After obtaining written informed consent the
investigator will initiate washout of prior psychotropic medications. After the washout of
prior psychotropic medications has been completed the investigator must ensure that the
subject is no longer taking psychotropic medication for at least 14 days prior to the
randomization visit. In addition the investigator must ensure that screening visit procedures
(with the exception of obtaining informed consent) are completed within 14 days of the
Potential subjects will be approached during a regularly scheduled clinic visit, upon
referral from another physician, or in response to research advertisements. Those who call in
will participate in a short phone pre-screen. This allows us to determine if the person fits
the most limiting inclusion/exclusion criteria before requesting they dedicate a longer
period of time for an in-person screen. Additionally it gives interested individuals the
opportunity to learn more about the study and to review the consent form with family,
friends, and other physicians prior to coming in for the screen and making a final decision
regarding study enrollment. Once the subject has given informed consent, the screening
process for the study will commence.
Subjects who fulfill entry criteria will be randomized to receive ONE of the following 4
treatments in a double-blind fashion: PD 0332334 225 mg BID, PD 0332334 300 mg BID, placebo,
and paroxetine 20 mg QAM. PD 0332334 will be titrated up in the PD 0332334 225 mg BID and PD
0332334 300 mg BID treatment groups. The titration of PD 0332334 will be from 125 mg in the
beginning of the study. In addition the PD 0332334 225 mg BID and PD 0332334 300 mg BID
treatment groups will be titrated down at the end of the study. The 20 mg daily dose of
paroxetine used in this study is based on the approved label for the use of paroxetine in
patients with GAD. Doses were selected for this Phase 3 study based on safety and efficacy
information known about PD 0332334 and pregabalin (PGB), an α2δ ligand approved for the
treatment of GAD in Europe
The subjects enrolled will be men and women ages 18 to 65 who meet DSM-IV criteria for
generalized anxiety disorder with a preponderance of anxious symptoms over depressive
De-identified blood samples will be collected from study subjects at Screening (Visit 1)
according to the standard Molecular Profiling supplement to the protocol. Participation in
this component is optional for study subjects. Samples may be utilized in the future to
investigate GAD (generalized anxiety disorder) genetics, expression metabonomic and protein
biomarker profiles, drug-response, or other genetic or biomarker questions. [Metabonomics:
The study of metabolic responses to drugs, environmental changes and diseases. Metabonomics
is an extension of genomics (concerned with DNA) and proteomics (concerned with proteins). ]
Additionally, partners of male participants who become pregnant during the course of the
study, will be requested to participate in order for the sponsor to collect safety
information and understand the effects, if any, that PD 0332334 may have on her pregnancy or
the fetus. Details of the this sub-study are described in the separate 'pregnant partner'
consent form. Pregnant partners will be be asked to sign a separate HIPAA and consent form in
order to participate.
The investigators have recently received notification of an SAE (Serious adverse event) at
another site that has already begun recruitment for this study. The MediWatch report for that
SAE is included as a Supporting document on WEBRIDGE. Additionally, a protocol change
clarifying the procedures to collect lab information to calculate the estimate Creatinin
CVlearance (CLer) has been submitted. This document has been added as a supporting document
Official title: A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Hamilton Anxiety Scale
Minimum age: 18 Years.
Maximum age: 65 Years.
Subjects must meet all of the following inclusion criteria to be eligible for enrollment
into the study:
1. Diagnosis of GAD (Diagnostic and Statistical Manual-IV [DSM-IV], 300. 02) as
established by the clinician.
2. Subjects must have a HAM-A total score ≥20 at the screening (V1) and randomization
(V2) visits. Subjects must also have a Covi Anxiety Scale score of ≥9 and a Raskin
Depression Scale score ≤7 at the Screening (V1) visit to ensure predominance of
anxiety symptoms over depression symptoms.
3. Otherwise healthy men or non-pregnant, non-lactating women (women must be using a
hormonal or barrier method of contraception or be postmenopausal or surgically
sterilized). Healthy is defined as no other clinically relevant abnormalities
identified by a detailed medical history, full physical examination including sitting
blood pressure (BP) and heart rate measurement, 12-lead ECG, and clinical laboratory
4. Age 18 to 65 years, inclusive.
5. All women must have negative pregnancy tests at the Screening (V1) and Randomization
6. Evidence of a personally signed and dated informed consent document indicating that
the subject has been informed of all pertinent aspects of the study.
7. Subjects who are willing and able to comply with scheduled visits, treatment plan,
laboratory tests, and other study procedures.
Subjects presenting with any of the following will not be included in the study:
1. Subjects with evidence or history of clinically significant hematological, renal,
endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, pancreatic,
neurologic, active infections, immunological, or allergic disease (including drug
2. Any of the following current (within the past 6 months through the present) DSM-IV
Axis I diagnoses:
- Major depressive disorder;
- Obsessive compulsive disorder;
- Panic disorder;
- Posttraumatic stress disorder;
- Caffeine-induced anxiety disorder;
- Alcohol or substance abuse or dependence unless in full remission for at least 6
- Social anxiety disorder.
3. Any of the following past or current DSM-IV Axis I diagnoses:
- Psychotic disorder;
- Delirium, dementia, amnestic, and other clinically significant cognitive
- Bipolar or schizoaffective disorder;
- Cyclothymic disorder;
- Dissociative disorders.
4. Antisocial or borderline personality disorder.
5. Serious suicidal risk per the clinical investigator's judgment. (Note: The Suicidality
module of the MINI diagnostic interview and the C-SSRS should be used as aids to the
assessment of suicidality, but do not replace overall clinical judgment in
determination of suicidal risk).
6. Current use of psychotropic medications (ie, drugs normally prescribed for depression,
mania, anxiety, insomnia, or psychosis) that cannot be discontinued 2 weeks prior to
randomization. Fluoxetine is prohibited within 5 weeks of randomization. In the event
of inadvertent administration of psychotropic medications during the 2 weeks prior to
randomization, continued eligibility will be assessed on a case by case basis by the
investigator and the medical monitor.
7. Use of drugs, supplements, prescription or nonprescription, or food that have
psychoactive properties. In the event of inadvertent use of such products during the 2
weeks prior to randomization, continued eligibility will be assessed on a case by case
basis by the investigator and the medical monitor. In addition, following a discussion
of the individual case between the medical monitor and the investigator, the medical
monitor may allow minimal anxiolytic medication (for example a benzodiazepine) use for
subjects who experience significant intolerable anxiety during the final week of the
study (Days 64-71).
8. Subjects who have been treated with monoamine oxidase inhibitors in the 14 days prior
to the baseline visit.
9. Regular use of benzodiazepines during the 3 months prior to Screening (for at least 5
out of 7 days per week).
10. Subjects initiating formal psychotherapy within 3 month prior to screening who intend
to continue formal psychotherapy during the study. This includes psychodynamic,
cognitive, and interpersonal therapies.
11. Positive drug tests at Screening (V1) or Randomization (V2) visits for any of the
following substances or classes of compounds: amphetamines, barbiturates, opiates,
benzodiazepines, sedatives and hypnotics, cocaine, phencyclidine (PCP), cannabinoids,
or other illegal or illicit drugs. An exception to the exclusion for a positive
benzodiazepine, opiate, or sedative and hypnotic drug test at the Screening (V1) visit
may be granted by the Pfizer medical monitor if written evidence of a valid, current
prescription is presented.
12. Any condition possibly affecting drug absorption (eg, gastrectomy).
13. Subjects with a current seizure disorder.
14. Subjects with a history of life-threatening neoplasms within 5 years prior to study
entry, other than carcinoma in situ of the cervix or basal cell carcinoma of the
15. Subjects with hypothyroidism or hyperthyroidism, except subjects who are euthyroid and
have been on stable doses of thyroid replacement for 6 months or more.
16. Subjects with any clinically unstable hematological, autoimmune, endocrine,
neurological, renal, hepatic, retinal, gastrointestinal, or cardiovascular disorder.
17. Subjects with uncontrolled narrow angle glaucoma.
18. Subjects with a known hypersensitivity to paroxetine.
19. History of allergy or intolerance to paroxetine.
20. Subjects with a prior history of insufficient response to paroxetine in the treatment
of generalized anxiety disorder (with an adequate trial of therapy).
21. Pregnant or nursing females; females of childbearing potential who are unwilling or
unable to use an acceptable method of contraception for the duration of the study.
22. Treatment with an investigational drug within 60 days preceding the first dose of
23. Estimated creatinine clearance (CLcr) <55 mL/min (using Cockcroft-Gault equation).
24. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels >3 times the
upper limit of normal at Screening (V1).
25. Male and Female subjects with a screening 12-lead ECG demonstrating QTcF (Fredericia's
correction) >450 msec, if confirmed with an unscheduled repeat 12-lead ECG's at the
screen visit. In the event of discrepant QTcF values (i. e., >450 msec and <450 msec)
after repeat unscheduled 12-lead ECG at screen, a decision with regards protocol
eligibility will be made on a case by case basis between the investigator and medical
26. History of lack of efficacy for treatment of GAD with, or allergy or intolerance to,
other α2δ drugs (pregabalin, gabapentin).
27. Blood donation of approximately 1 pint (500 mL) or more within 56 days prior to
28. Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with trial participation or
investigational product administration or may interfere with the interpretation of
trial results and, in the judgment of the investigator, would make the subject
inappropriate for entry into this trial.
Locations and Contacts
Lisa H Glassman, B.A., Phone: 310-423-0735, Email: email@example.com
Cedars-Sinai Medical Center Department of Psychiatry and Behavioral Neurosciences, Los Angeles, California 90048, United States; Recruiting
Phone: 310-423-6515, Email: firstname.lastname@example.org
Mark H Rapaport, M.D., Principal Investigator
Starting date: October 2008
Ending date: April 2010
Last updated: February 3, 2009